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A B S T R A C T
Viral necrosis virus (NNV) or nodavirus causes fish viral encephalopathy and retinopathy worldwide. In some
cases, mortalities in aquaculture industry can reach up to 100%, some species being especially sensitive as is the
case of European sea bass (Dicentrarchus labrax), one of the main cultured species in the Mediterranean, with the
consequent economical loses. Development of new vaccines against NNV is in the spotlight though few re-
searches have focused in European sea bass. In this study we have generated a recombinant NNV (rNNV) vaccine
produced in Escherichia coli expressing the capsid protein and administered it to European sea bass juveniles by
two different routes (intraperitoneal and oral). The last being considered non-stressful and desired for fish
farming of small fish, which in fact are the most affected by NNV. Oral vaccine was composed of feed pellets
containing the recombinant whole bacteria, and injected vaccine was composed of recombinant bacteria pre-
viously lysed. Our results revealed production of specific anti-NNV IgM following the two vaccination proce-
dures, levels that were further increased in orally-vaccinated group after challenge with NNV. Genes related to
interferon (IFN), T-cell and immunoglobulin markers were scarcely regulated in head-kidney (HK), gut or brain.
Vaccination by either route elicited a relative survival response of 100% after NNV challenge. To our knowledge,
this is the first report of a recombinant vaccine followed by no purification steps which resulted in a complete
protection in European sea bass when challenged with NNV.
1. Introduction
In the current scenario of increasing world population, together
with greater awareness of the benefits of fish consumption, aquaculture
activity has become essential to cover fish-products demand.
Production values can be seriously compromised by the occurrence of
viral diseases, which can be rapidly spread throughout fish specimens
and farms. This is the case of the nodavirus (NNV), which causes Viral
Encephalopathy and Retinopathy (VER) disease, which has growth in
importance due to the wide range of target species (up to 120 species
from marine and freshwater environments) and the massive rate mor-
talities it can cause (up to 100% in some species such as European sea
bass Dicentrarchus labrax) [1]. NNV cause cellular vacuolation and
necrosis in brain and retina, and symptoms include abnormal swim-
ming, altered buoyancy, low feed ingestion and darker coloration
among others, being especially important in larvae and juvenile fish
stages [2,3]. NNV is composed by a non-enveloped capsid, formed by
180 subunits of a single protein, containing two ssRNA molecules of
positive sense [4]. The RNA1 codifies a RNA-dependent RNA poly-
merase, also known as “protein A″, which drives the replication of the
virus; and RNA2 codifies the capsid protein [1,5]. There is also a sub-
genomic RNA3 derived from RNA1, encoding for B1 and B2 proteins,
which have a role in preventing cellular RNA silencing and premature
death [6–10]. Four different genotype strains have been identified
being red-spotted grouper nervous necrosis virus (RGNNV) the most
common genotype found in the Mediterranean waters.
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Horizontal and vertical transmission of the NNV has been demon-
strated, and the industry has applied different control strategies to
avoid spreading of NNV, such as ozone sterilization, control of brood-
stocks and development of vaccines [1,11–13]. In practice, the appli-
cation of some of these procedures can be difficult, being the prevention
by means of vaccination the most promising method to control virus
disease [3]. Currently, there is only one commercial vaccine against
NNV (PharmaQ) and high efforts to develop novel and more effective
vaccines to prevent NNV outbreaks and dissemination are being made
and can be found in the literature including attenuated, inactivated,
recombinant and DNA vaccines [1,13].
Recombinant NNV vaccines are based in the production of the
capsid protein, the only one with antigenic properties. This could be
produced in either prokaryotic or eukaryotic organisms, partial or
complete, and forming virus-like particles (VLPs) or not. A number of
studies have shown that both innate and adaptive immune defence as
well as survival against NNV challenged can be stimulated by purified
recombinant vaccines. The suitability of purified recombinant NNV
capsid protein vaccines has been confirmed after injection for several
fish species including turbot (Scophthalmus maximus) [14], Atlantic
halibut (Hippoglossus hippoglossus) [15,16], European sea bass [17,18],
Asian sea bass (Lates calcarifer) [19] or several grouper species (Epine-
phelus spp.) [20–29]. In general, they offered medium-good protection
upon infection but not all of them led to fish antibody production. Most
of these vaccines were produced using the prototype Escherichia coli as
the biofactory but few studies also showed good results when the
vaccine was produced by the bacterium Vibrio anguillarum [24] or by
the yeast Saccharomyces cerevisiae [25,26]. In addition, most of the
vaccines were administered together to adjuvants and by intramuscular
or intraperitoneal injection routes, which is not exempt of fish stress
and suffering due to handling and injection, being particularly labor-
ious and risky in larvae, the most susceptible stages for NNV.
Oral vaccines have arisen as a practical solution to fish vaccination
in the farms. In this sense, several oral vaccines have been successfully
documented against NNV. Thus, DNA vaccines were encapsulated and
orally administered and partially protected Asian sea bass [30] or
European sea bass [31] upon NNV challenge. For recombinant oral
vaccines, they were produced in bacteria or yeast and added to the diet
after protein purification, or by the encapsulation of these micro-
organisms into Artemia [23–27]. Based on the potential application of
oral vaccines and the few studies generating and evaluating NNV vac-
cines in European sea bass the aim of this study was to develop a re-
combinant vaccine against NNV (administered by both injected and
oral routes), in order to improve protection of European sea bass, a
susceptible and economically important species reaching up to 100% of
mortality by NNV. Our vaccine was developed using E. coli as antigen
expression host, which was applied without any purification step, thus
the bacteria acting as vaccine vehicle and as biological adjuvant as well.
2. Material and methods
2.1. Animals
Healthy European sea bass juveniles (Dicentrarchus labrax; 10–12 g
body weight) were purchased form a regional hatchery with clear his-
tory of NNV infections and transported to the University of Murcia
(Spain). Fish were kept in 75 L running seawater (28‰ salinity) aquaria
at 24±2 °C, with a 12 h light:12 h dark photoperiod and fed daily with
3% biomass of a commercial pellet diet (Skretting). Before sampling, all
specimens were anesthetized with 40 μL/L of clove oil, completely bled
and immediately beheaded and weighed. All animal studies were car-
ried out in accordance with the Guidelines of the European Union
Council (2010/63/UE), the Bioethical Committee of the University of
Murcia (Permit Number: A13150104) and the Instituto Español de
Oceanografía (Permit Number: 2010/02) for the use of laboratory ani-
mals.
2.2. Nodavirus (NNV) stocks
Nodavirus (NNV; strain It/411/96, genotype RGNNV) was propa-
gated in the E−11 cell line. Cells were inoculated with NNV and in-
cubated at 25 °C until the cytopathic effect (CPE) was extensive. The
supernatant was harvested and centrifuged to eliminate cell debris.
Virus stocks were titrated in 96-well plates before use in the experi-
ments [32].
2.3. Production of recombinant NNV (rNNV) vaccine
We amplified the RNA2 encoding the capsid protein of RGNNV by
PCR (see Supplementary Table 1 for primers) and the product ligated
into the pBADM-11 vector (EMBL) using NcoI and EcoRI restriction
enzymes to produce the N-terminal His-tagged NNV capsid protein
(rNNV). Self-ligated or empty plasmid was used as negative control.
Plasmid was then used to transform TOP10 Escherichia coli bacteria.
Clones containing the plasmid were selected by ampicillin resistance
and confirmed by PCR. Recombinant bacteria were grown in Luria
broth (LB) and protein production induced by L-arabinose incubation
for 4 h. Proteins were electrophoresed and blotted to nitrocellulose
membrane being total proteins stained by Ponceau S solution and the
rNNV protein identified by western blotting using a commercial anti-
His antibody (Invitrogen) following standard techniques.
2.4. Fish vaccination
For vaccine preparation, bacterial cultures were induced for rNNV
overproduction, washed twice with phosphate buffer (PBS) and pro-
cessed for vaccination by either oral or injection routes. For oral vac-
cination, whole bacteria were added to the commercial diet at 1010 cfu/
g fed and cod oil (100ml per kg diet) was added to seal the pellets. For
intraperitoneal (ip) vaccination, bacteria at 1011 cfu/mL were sonicated
for cell lysis on ice.
Prior to the fish vaccination the absence of NNV was confirmed by
routine histology and PCR in the brain of 6 fish specimens. European
sea bass fish specimens were randomly divided into 12 aquaria (75 L
each) with 30 fish each forming six experimental groups in duplicate.
For oral vaccination, one group was fed with the commercial diet
(control) or the diet containing bacteria without NNV (oral control) or
bacteria producing the rNNV vaccine (oral rNNV). Fed was admini-
strated at a rate of 3% biomass for 3 consecutive days and a boost at day
14. For ip vaccination, fish were gently sedated by 20 μL/L of clove oil
and each fish received a single ip injection with 100 μL of PBS (control),
bacterial lysate without NNV (ip control) or the rNNV bacterial lysate
(ip rNNV). Fish were also boosted at day 14. After vaccination, fish
(n= 6 fish/group and time) were sampled 1, 15 and 30 days post-
vaccination (dpv). Blood was obtained from the caudal peduncles and
serum samples by centrifugation at 10,000 g for 10min at 4 °C and
immediately stored at −80 °C until use. Head-kidney (HK), posterior
gut and brain were removed by dissection, immediately frozen in
TRIzol Reagent (Life Technologies) and stored at −80 °C until use.
2.5. NNV challenge
Thirty days after vaccination, the remaining fish (20 per aquaria)
received a single intramuscular injection of 100 μL culture medium
containing 106 TCID50/fish of the same NNV isolate since this route of
infection has been proven to be the most effective. Mortality was re-
corded daily as the cumulative mortality and relative percentage of
survival (RPS) determined. Samples of serum and brain (n= 6/group
and time) were also taken 2 days post-infection (dpi) and processed as
described above.
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2.6. Specific anti-NNV IgM levels
Serum specific immunoglobulin M (IgM) levels against NNV were
analysed following a previously used protocol [33]. Briefly, 100 μL of
purified NNV preparation diluted 1:5 with 50mM carbonate-bicarbo-
nate buffer pH 9.6 was used to coat flat-bottomed 96-well plates
overnight at 4 °C. After three rinses with PBS-T (PBS with 0.05%
Tween-20), the plates were blocked for 2 h at room temperature with
PBS containing 3% bovine serum albumin, followed by four rinses with
PBS-T. Then, 100 μL of 1:100 serum dilutions in PBS-T were incubated
for 2 h at room temperature, followed by five rinses with PBS-T. The
plates were then incubated with the optimal dilutions of mouse anti-sea
bass IgM monoclonal antibody (Aquatic Diagnostics Ltd.) and sec-
ondary anti-mouse IgG-HRP (Sigma-Aldrich). The absorbance was read
at 450 nm in a plate reader (BMG Labtech). Negative controls consisted
of samples without serum or without coating. Sera from NNV-infected
sea bass were also used as positive control.
2.7. Gene expression
Total RNA was isolated from TRIzol Reagent frozen samples fol-
lowing the manufacturer's instructions. One microgram of total RNA
was treated with DNAse I to remove genomic DNA, and the first strand
of cDNA was synthesized by reverse transcription using the SuperScript
IV Reverse Transcriptase (Thermo Fisher) with random hexamers
(Thermo Fisher).
The expression of the genes coding for (i) type I IFN pathway, (ii) B
cell markers and immunoglobulins and (iii) T cell markers proteins
were analysed by real-time PCR, performed with an ABI PRISM 7500
instrument (Applied Biosystems) using SYBR Green PCR Core Reagents
(Applied Biosystems) as previously described [31]. The specific primers
used were designed using the Oligo Perfect software tool (Invitrogen)
and are shown in Supplementary Table 1. Prior to the experiments, the
specificity of each primer pair was studied using positive and negative
samples. A melting curve analysis of the amplified products validated
the primers for specificity. Negative controls with no template were
always included in the reactions. For each mRNA sample, gene ex-
pression was corrected by the geometric average of the expression of
two endogenous genes [elongation factor 1 alpha (ef1a) and tubulin
alpha (tuba)] in each sample and expressed as 2−ΔΔCt, where ΔΔCt is
determined by subtracting the endogenous Ct geometric average value
from the target Ct and referring to the respective control group.
2.8. Statistical analysis
Data were analysed by a t-Student test to establish differences be-
tween control and vaccinated groups at each time point (P≤ 0.05).
Data are represented as the mean ± standard error of the mean (SEM).
Cumulative mortality was represented for both groups as mean ± SEM
(n=2 replicates). Statistical analyses were conducted using SPSS
Statistical Software System version 15.0 (SPSS Inc.).
3. Results
3.1. rNNV production
Recombinant bacteria were selected and the production of rNNV
protein fused to N-terminal 6×His tested by electrophoresis and
western blotting (Fig. 1). Results showed that bacteria contain few
positive bands before induction with arabinose. After induction, Pon-
ceau S staining for total proteins (Fig. 1A) showed a very prominent
band of around 48 kDa, which corresponds to the recombinant NNV
capsid protein (Fig. 1B) as evidenced by the immunoblotting.
3.2. rNNV vaccine increases specific IgM levels
The levels of specific anti-NNV IgM was determined in European sea
bass serum by ELISA. After 30 days of vaccination, both administration
routes produced significant increments in the specific anti-NNV IgM
although the intraperitoneal route produced higher antibody levels
(Fig. 2). In addition, when vaccinated fish were challenged with NNV
the IgM titters were further increased, being highest now in fish vac-
cinated by the oral route.
3.3. rNNV vaccination slightly affects the immunity at gene level
In Fig. 3, we show the fold change in the expression of genes related
to IFN (mx and isg15), immunoglobulin (ighm and ight) and T-cell
markers (cd8a and cd4) in HK, posterior gut and brain. Surprisingly,
very little differences reached significance. Thus, ip vaccination re-
sulted in decreased ight transcription in the HK after 30 dpv while oral
vaccination did in the cd4mRNA levels at 30 dpv and 2 dpi. P values for
the comparison between groups is denoted in Supplementary Table 2.
3.4. Recombinant vaccine elicits great protection after challenge
Fish were challenged at 30 dpv (Fig. 4) and the mortalities recorded.
In the control group, fish deaths were recorded from day 3 until day 10,
reaching a low mortality of 33% and showing typical disease symptoms
(data not shown), while in the rNNV vaccinated group by either route
no fish death was recorded. Therefore, the rNNV vaccination elicited a
RPS (relative percentage of survival) of 100%.
4. Discussion
Aquaculture provides slightly over half of the fish production
worldwide, being an industry of fast growing [34], therefore occurrence
of viral outbreaks and associated mortality would result in important
Fig. 1. Recombinant NNV capsid vaccine (rNNV) production in bacteria.
Bacteria were lysed, electrophoresed and proteins transferred to a nylon
membrane, which was either stained with Ponceau S for total protein (A) or
used for immunoblotting with anti-His antibody (B). Bacterial cultures before
and after induction with L-arabinose were tested. M, marker.
D. Gonzalez-Silvera, et al. Fish and Shellfish Immunology 88 (2019) 458–463
460
economic loses. In this context, current research is focused in finding
cost-effective antiviral treatments, being prevention through vaccina-
tion the most promising methodology. Different types of vaccines
against NNV have been generated, the recombinant vaccines providing
encouraging results. Thus, bacteria can express peptides or the com-
plete capsid protein, which might auto-assemble to form VLPs [35,36]
resembling native virus but without containing viral genome, which are
further purified for vaccination by intraperitoneal injection. Never-
theless, handling and anesthetizing are stressful procedures, and the
injection is not practical in small fish, which indeed, are the most
susceptible to disease. By contrast, oral administration can be applied to
a high number of juveniles and larvae at the same time, saving time and
avoiding stress to fish and should be further explored.
We have developed and tested a recombinant vaccine, delivered
without any purification steps, thus E. coli acted as an adjuvant. In
general terms, we obtained the same efficacy of our recombinant vac-
cine independently of the administration method, which demonstrates
the stability and the antigenic properties of the synthesized capsid
protein delivered without any purification steps. To our knowledge, this
is the first report of a recombinant vaccine administered to European
sea bass providing a 100% survival upon NNV challenge. Our results
surpass most of those using purified recombinant NNV vaccines
[14,16–19,23–27]. The success of our vaccine can be partly explained
by the generation of specific anti-NNV IgM in vaccinated fish, which
further responded to NNV infection increasing IgM titters, especially in
the oral vaccinated group. Synthesis of either total and/or neutralizing
specific antibodies against nodavirus has been already found in Eur-
opean sea bass and other fish species upon nodavirus vaccination. In
most of the studies NNV resistance has been achieved after vaccination
with recombinant NNV vaccines that is partly explained by increased
antibody levels [14,16–19,23–27]. This fact points to the correct in-
duction of fish immunity by the recombinant proteins and generation of
IgM. Unfortunately, our results about gene expression are somehow
contradictory since we failed to detect important differences in the
expression of the studied genes in comparison with control groups.
Perhaps, this is due to high fish-to-fish variability and the fact that
control groups also received whole or lysed E. coli, and it could be
acting as a potent immunostimulant, regulating the expression of the
studied genes and masking a possible regulation due to the rNNV
protein in the vaccine. Previous studies have demonstrated early up-
regulation of some key immune genes encoding type-I IFN genes, Ig, T-
cell markers or cytokines among others after vaccination with re-
combinant or inactivated NNV vaccines [13,21,33,37]. In sharp con-
trast to our data, although it is known the early induction and protec-
tive role of type-I IFN by NNV infection or vaccines [13,38–40] few
studies have documented increased expression of IFN-related genes 2–4
weeks after vaccination with NNV [31,41,42]. This could be due to the
presence of viral RNA, or a very reduced ability to viral proliferation,
from the inactivated vaccine formulations. Unfortunately, any study has
documented this late expression of IFN-related genes after vaccination
with recombinant vaccines, which could be due to the absence of viral
RNA. Interestingly, inactivated NNV vaccination of European sea bass
resulted partly protective with increased antibacterial and antiviral
activities and IgM levels in serum though the expression of immune
genes in the HK was down-regulated [33] as it occurs in this study.
Strikingly, though this was not significant, oral injection of rNNV re-
sulted in a general pattern of transcript down-regulation in the gut 30
dpv while this fact was reversed after challenge, suggesting some gut
specific immune response. In addition, though the viral challenge
produced little mortality all the genes evaluated in vaccinated Eur-
opean sea bass specimens showed a decreased transcription in the
brain. This suggest that the low levels of NNV were probably cleared by
the circulating IgM in vaccinated fish before the virus can reach the
target tissues. Further studies are needed to understand the mechanism
by with NNV vaccines operate in European sea bass.
To conclude, we have developed an E. coli-produced recombinant
vaccine for NNV, suitable to be administered without any purification
by both oral and intraperitoneal injection routes, obtaining a survival
rate of 100% in European sea bass juveniles. Mechanistically, vacci-
nation elicited specific anti-NNV IgM but failed to affect the expression
of immune transcripts, what deserves further studies to be understood.
Both administration routes showed similar results, demonstrating that
oral vaccination can be successfully applied to protect European sea
bass from NNV, which is more appropriate for large scale vaccination
avoiding stressful, labour intensive and costly procedures.
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